Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic …
… value of this molecular signature cannot be … tumors and tumor immune microenvironment
in relation with clinical outcome in order to identify solid predictive markers for immunotherapy…
in relation with clinical outcome in order to identify solid predictive markers for immunotherapy…
Enhancing therapeutic approaches for melanoma patients targeting epigenetic modifiers
M Gracia-Hernandez, Z Munoz, A Villagra - Cancers, 2021 - mdpi.com
… Epigenetic alterations can also lead to immune evasion and … to treat patients that do not
respond or become resistant to first… molecules in melanoma cells and decreased tumor growth in …
respond or become resistant to first… molecules in melanoma cells and decreased tumor growth in …
The local immune response in melanoma. In situ analysis of the micro-environmental immune-signature of primary melanoma.
F Bosisio - 2018 - boa.unimib.it
… and to keep the patient on a durable remission or on a stable … , but integrated also with
molecular melanoma-cell centered … tissue section the immune microenvironment associated with …
molecular melanoma-cell centered … tissue section the immune microenvironment associated with …
[HTML][HTML] Molecular characterization of the clinical and tumor immune microenvironment signature of 5-methylcytosine-related regulators in non-small cell lung cancer
T Liu, L Guo, G Liu, X Hu, X Li, J Zhang… - Frontiers in Cell and …, 2021 - frontiersin.org
… For background correction and normalization, the Robust … of immunotherapy outcomes.
However, the survival analysis … Epigenetic alterations are associated extensively with the …
However, the survival analysis … Epigenetic alterations are associated extensively with the …
Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
… for the treatment of patients with melanoma after an … immunotherapy-sensitive cancer
subtypes [27, 28]. Staining was negative in one of our patients and it could not be performed due …
subtypes [27, 28]. Staining was negative in one of our patients and it could not be performed due …
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study
…, P Queirolo, Italian Melanoma Intergroup (IMI) - … , Immunotherapy, 2019 - Springer
… among patients in irCR/irPR (immune-related complete/partial … However, the benefit in terms
of long-lasting disease control … (ALC) [18], and epigenetic features of melanoma and tumor …
of long-lasting disease control … (ALC) [18], and epigenetic features of melanoma and tumor …
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab
… Molecular and epigenetic features of melanomas and tumor immune microenvironment
linked to durable remission to ipilimumab-based immunotherapy in metastatic patients …
linked to durable remission to ipilimumab-based immunotherapy in metastatic patients …
[HTML][HTML] Biomarkers for response of melanoma patients to immune checkpoint inhibitors: a systematic review
CAC Jessurun, JAM Vos, J Limpens… - Frontiers in oncology, 2017 - frontiersin.org
… of advanced melanoma patients have durable responses to … mostly due to an unclear
description of follow-up data of patients … should display an active immune microenvironment. In 12 …
description of follow-up data of patients … should display an active immune microenvironment. In 12 …
Genetic and epigenetic biomarkers of immune checkpoint blockade response
Q Xiao, A Nobre, P Piñeiro… - Journal of clinical …, 2020 - mdpi.com
… of JAK family members render melanoma resistant to IFN-γ … be related to progressive disease
in melanoma patients. … of the anti-tumor immune reactivation could be related to the post-…
in melanoma patients. … of the anti-tumor immune reactivation could be related to the post-…
[HTML][HTML] Molecular immunotherapy: promising approach to treat metastatic colorectal cancer by targeting resistant cancer cells or cancer stem cells
… response, they are associated with virtually no activity in patients with pMMR/… remission
rates in metastatic CRC (60). Recently, modern molecular analysis has shown that melanoma …
rates in metastatic CRC (60). Recently, modern molecular analysis has shown that melanoma …